Milrinone Explained: The Inotrope for Beta-Blocked Hearts

Milrinone is a phosphodiesterase-3 inhibitor and the go-to inotrope when patients are on beta-blockers or have right ventricular failure. In this deep dive, we cover the pharmacology, mechanism, clinical applications, and critical differences between milrinone and dobutamine. 🎯 What You'll Learn: • PDE-3 inhibition mechanism (non-adrenergic) • Why milrinone works despite beta-blockade • Inodilator profile: inotropy + vasodilation • Milrinone vs dobutamine: when to choose which • Use in cardiogenic shock and ADHF • Right ventricular failure and pulmonary vasodilation • Dosing and renal adjustments • PROMISE trial and chronic use dangers • Thrombocytopenia monitoring • Combining with vasopressors (NE) • MCS considerations (ECMO, Impella, IABP) ⚠️ Key Takeaways: ✓ Works independently of beta receptors (PDE-3 inhibitor) ✓ First-line inotrope for beta-blocked patients ✓ Reduces both SVR and PVR (afterload reduction) ✓ Longer half-life than dobutamine (harder to wean) ✗ Hypotension risk (often needs concurrent NE) ✗ Chronic use increases mortality (PROMISE trial) ✗ Thrombocytopenia in 2-4% of patients 🔬 Evidence-Based Critical Care Education Designed for ICU physicians, cardiology fellows, critical care NPs/PAs, nurses, pharmacists, and cardiovascular specialists. --- 🩺 PULSE & PRESSORS Where critical care gets crystal clear. Reflecting on the marvels of the human body. --- #Milrinone #Inotropes #CriticalCare #ICU #CardiogenicShock #HeartFailure #Pharmacology #BetaBlockers #RightHeartFailure #PDE3Inhibitor #Dobutamine #Hemodynamics #MedicalEducation #ICUDrips #CardiovascularMedicine #ECMO #IntensiveCare #CCM #MedEd #FellowshipEducation